PTK 2015 Banner 
2015 Peptalk M Banner 

Pipeline Two Icon Pipeline Two Header 

Cambridge Healthtech Institute’s Inaugural
Cancer Targets for Antibody Therapeutics
Discovery, Engineering and Optimization of Next-Generation Oncology Targets
January 19-20, 2015


The science and technology of antibody engineering have brought forth a new era of therapeutic antibodies in oncology, with new product formats and an intense interest in immune system modulation now at the forefront of many companies’ development efforts. PepTalk’s new Cancer Targets for Antibody Therapeutics conference explores new directions in the discovery of emerging and challenging targets in this space – and the steps required to develop these into next-generation therapeutics for patients.

Preliminary Agenda 


NEW APPROACHES TO TARGETING THE TUMOR MICROENVIRONMENT 


KEYNOTE PRESENTATION 

Multifunctional Angiogenesis Inhibitors Designed from Non-Antibody Scaffolds 

Jennifer R. Cochran, Ph.D., Associate Professor, Bioengineering and Chemical Engineering, Stanford University  

Manipulating the Tumor Microenvironment to Enhance Effector Function for Improved Antibody Efficacy in Patients 

Stephen Beers, Ph.D., Senior Research Fellow, Faculty of Medicine, University of Southampton 


ENGINEERING ANTIBODIES FOR IMPROVED TUMOR PENETRATION 

A Cell-Penetrating Antibody Technology Platform: Making the Undruggable Druggable  

Hua Eleanor Yu, Ph.D., Professor, Cancer Immunotherapeutics & Tumor Immunology, City of Hope National Medical Center  

The Effect of Molecular Weight, PK and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs 

Ruth Muchekehu, Ph.D., Research Scientist, Vertex Pharmaceuticals  

How to Leverage Oncogene Addiction: Targeted Biological Therapy Inducing Growth Factor Receptor Internalization and Degradation 

John Haurum, M.D., D.Phil., CEO, F-star GmbH & F-star Biotechnology Ltd. 


EMERGING TARGETS 

Targets for Antibodies in Neuro-Oncology: Getting Past the Blood-Brain Barrier 

Lois Lampson, Ph.D., Associate Professor of Surgery, Brigham and Women's Hospital  

Alternative Immune Models for Generating Novel Antibodies to Highly Conserved Oncology Targets 

William “Jonny” Finlay, Ph.D., Director, Pfizer 

SAR650984, a CD38 Monoclonal Antibody for Selected CD38+ Hematological Malignancies  

Francisco Adrian, Ph.D., Section Head, Sanofi Oncology  

A Novel T Cell Bispecific Antibody Targeting EGFRvIII to Specifically and Potently Kill Tumor Cells in vitro and in vivo 

Eugene Zhukovsky, Ph.D., CSO, Research, Affimed Therapeutics AG 

Drugging the Undruggable: Using Knowledge-Based Design to Develop Antibodies Against Difficult Targets  

Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center  

Selection of Antibodies for T Cell Redirected Killing 

Diego Ellerman, Senior Research Associate, Protein Chemistry, Genentech, a Member of the Roche Group  


DISCOVERY AND ENGINEERING OF IMMUNOMODULATORY ANTIBODIES 


FEATURED PRESENTATION 

Monoclonal Antibodies as the Foundation of the Immunotherapy Revolution  

David Meininger, Ph.D., Executive Director, Business Development & Licensing, Merck  

Engineering a Novel, Multivalent Fusion Protein that Potently Agonizes a TNFSF Receptor 

Melissa Damschroder, Ph.D., Senior Manager, Research & Development, MedImmune  

Control of Regulatory T (Treg) Cell Function by Protein Kinase C-eta (PKC): A Novel Target for Cancer Immunotherapy  

Amnon Altman, Ph.D., Director, Scientific Affairs, Division of Cellular Biology, La Jolla Institute for Allergy and Immunology  

Discovery and Engineering of Novel Antibodies to Immune Checkpoints 

David J. King, Ph.D., CSO, AnaptysBio, Inc.